Bristol-Myers Squibb Company PFD CONV 2 BMYMP OTC

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) generated $14.16B in operating cash flow for fiscal year 2025. After capital expenditures of $1.31B, free cash flow was $12.85B.

Free cash flow margin was 26.7% of revenue. Cash conversion ratio was 2.01x, indicating earnings are backed by cash.

The company returned $5.05B in dividends to shareholders during the period.

Criteria supported by this page:

• HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (51/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (55/100) — Cash conversion ratio was 2.01x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 45/100 with 0/7 criteria passed.